Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07511062 · ClinicalTrials.gov registry record · Phase 1
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
A Phase 1 study, sponsored by Northside Hospital.
- Not yet
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07511062 is a Phase 1 study that has not yet begun recruiting, run by Northside Hospital. The registered enrollment target is 32 participants.
The verdict
NCT07511062, a Phase 1 study, has not yet begun recruiting, sponsored by Northside Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients
Interventions
- DRUG Venetoclax
- DRUG Decitabine
- DRUG Axatilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07511062
The ClinicalTrials.gov registry entry for NCT07511062 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT07511062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07511062 about?
NCT07511062 is a clinical study titled "Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML". Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients
What is the current status of trial NCT07511062?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-08-01. Estimated completion is 2030-08-01.
What interventions are being tested in trial NCT07511062?
The interventions under investigation include: Venetoclax (DRUG), Decitabine (DRUG), Axatilimab (DRUG).
Who is sponsoring clinical trial NCT07511062?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.